Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON TAP sub-study
2011-003832-30Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Mar 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etirinotecan pegol in breast cancer (2 arms), sponsored by Nektar Therapeutics. Primary endpoint: Overall survival. Started Mar 2012; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-003832-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003832-30.